Clinical Gastroenterology and Hepatology ( IF 12.6 ) Pub Date : 2022-07-19 , DOI: 10.1016/j.cgh.2022.06.030 Michael J. Buie , Joshua Quan , Joseph W. Windsor , Stephanie Coward , Tawnya M. Hansen , James A. King , Paulo G. Kotze , Richard B. Gearry , Siew C. Ng , Joyce W.Y. Mak , Maria T. Abreu , David T. Rubin , Charles N. Bernstein , Rupa Banerjee , Jesus K. Yamamoto-Furusho , Remo Panaccione , Cynthia H. Seow , Christopher Ma , Fox E. Underwood , Vineet Ahuja , Nicola Panaccione , Abdel-Aziz Shaheen , Jayna Holroyd-Leduc , Gilaad G. Kaplan , Domingo Balderramo , Vui Heng Chong , Fabián Juliao-Baños , Usha Dutta , Marcellus Simadibrata , Jamilya Kaibullayeva , Yang Sun , Ida Hilmi , Raja Affendi Raja Ali , Mukesh Sharma Paudel , Mansour Altuwaijri , Juanda Leo Hartono , Shu Chen Wei , Julajak Limsrivilai , Sara El Ouali , Beatriz Iade Vergara , Viet Hang Dao , Paul Kelly , Phoebe Hodges , Yinglei Miao , Maojuan Li
Background & Aims
The evolving epidemiologic patterns of inflammatory bowel disease (IBD) throughout the world, in conjunction with advances in therapeutic treatments, may influence hospitalization rates of IBD. We performed a systematic review with temporal analysis of hospitalization rates for IBD across the world in the 21st century.
Methods
We systematically reviewed Medline and Embase for population-based studies reporting hospitalization rates for IBD, Crohn’s disease (CD), or ulcerative colitis (UC) in the 21st century. Log-linear models were used to calculate the average annual percentage change (AAPC) with associated 95% confidence intervals (95% CIs). Random-effects meta-analysis pooled country-level AAPCs. Data were stratified by the epidemiologic stage of a region: compounding prevalence (stage 3) in North America, Western Europe, and Oceania vs acceleration of incidence (stage 2) in Asia, Eastern Europe, and Latin America vs emergence (stage 1) in developing countries.
Results
Hospitalization rates for a primary diagnosis of IBD were stable in countries in stage 3 (AAPC, −0.13%; 95% CI, −0.72 to 0.97), CD (AAPC, 0.20%; 95% CI, −1.78 to 2.17), and UC (AAPC, 0.02%; 95% CI, −0.91 to 0.94). In contrast, hospitalization rates for a primary diagnosis were increasing in countries in stage 2 for IBD (AAPC, 4.44%; 95% CI, 2.75 to 6.14), CD (AAPC, 8.34%; 95% CI, 4.38 to 12.29), and UC (AAPC, 3.90; 95% CI, 1.29 to 6.52). No population-based studies were available for developing regions in stage 1 (emergence).
Conclusions
Hospitalization rates for IBD are stabilizing in countries in stage 3, whereas newly industrialized countries in stage 2 have rapidly increasing hospitalization rates, contributing to an increasing burden on global health care systems.